Genocea Biosciences (GNCA) Tops Q3 EPS by 15c; Reports Cash and Cash Equivalents of $48.9M

Go back to Genocea Biosciences (GNCA) Tops Q3 EPS by 15c; Reports Cash and Cash Equivalents of $48.9M

Genocea Provides Third Quarter 2021 Corporate Update

October 28, 2021 7:00 AM EDT

GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues

Strong presence at the SITC 36th Annual Meeting

Conference call today at 8:30 a.m. E.T.

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq:... More